Sartorius Stedim: UBS reduces target price

(CercleFinance.com) - UBS maintains its 'neutral' rating on Sartorius Stedim Biotech shares, with a target price reduced from E276 to E232.
This new target implies 11% upside potential for the stock of the French supplier of products and services to the pharmaceutical industry.

After a Q1 publication deemed disappointing, the broker expects investors to remain cautious until there are consistent signs of recovery and a clear path towards targets for FY 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.